HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of islet β-Cells from Donors with Type 1 Diabetes by Russell, MA et al.
1 
HLA Class II antigen processing and presentation pathway components demonstrated by 
transcriptome and protein analyses of islet β-cells from donors with type 1 diabetes
Mark A. Russell1*, Sambra D. Redick2*, David M. Blodgett 3,5*, Sarah J. Richardson1, Pia Leete1, 
Lars Krogvold6, Knut Dahl-Jørgensen6, Rita Bottino7, Marcela Brissova8, Jason M. Spaeth9, 
Jenny Aurielle B. Babon3, Rachana Haliyur9, Alvin C. Powers 8,9,10, Chaoxing Yang2, Sally C. 
Kent3, Alan G. Derr4, Alper Kucukural4, Manuel G. Garber4, Noel G. Morgan1#, and David M. 
Harlan3#
1.
1.
Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, 
Devon, UK.
2. Program in Molecular Medicine, Diabetes Center of Excellence, University of 
Massachusetts Medical School, Worcester, MA, USA
3. Department of Medicine, Division of Diabetes, Diabetes Center of Excellence, University 
of Massachusetts Medical School, Worcester, MA, USA
4. Program in Bioinformatics, University of Massachusetts Medical School Worcester, MA, 
USA
5 Math and Science Division, Babson College, Wellesley, MA, USA
6. Pediatric Department, Oslo University Hospital, Oslo, Norway and Faculty of Medicine, 
University of Oslo, Oslo, Norway
7. Institute of Cellular Therapeutics, Allegheny-Singer Research Institute Department of 
Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.
8. Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt 
University Medical Center, Nashville, TN, USA
9. Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, 
TN, USA
10. Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA.
*- MAR, SDR, and DMB contributed equally to this work as 1st authors
#- NGM and DMH contributed equally as senior authors of this manuscript
Correspondence to: David M. Harlan, UMass Diabetes Center of Excellence, University of 
Massachusetts. E-mail: David.Harlan@umassmemorial.org
Guarantors: NGM and DMH are guarantors of this work, and as such, had full access to all the 
data in the study and take responsibility for the integrity of the data and the accuracy of the data 
analysis.
Keywords: autoimmunity, CIITA, DiViD, nPOD, Class II, transcriptome, islet cell, type 1 
diabetes
Running title: Class II β-cell expression in type 1 diabetes
Page 2 of 54Diabetes
 Diabetes Publish Ahead of Print, published online March 4, 2019
2 
Abbreviations: 
APC Antigen presenting cell
CIITA
Class I
Class II
Class II major histocompatibility complex transactivator
HLA Class I
HLA Class II
CTSS Cathepsin S
DiViD Diabetes Virus Detection study
EADB Exeter Archival Diabetes Biobank
ESAT End sequence analysis tool
FACS Fluorescence activated cell sorting
FFPE Formalin-fixed paraffin embedded
FSC-H, FSC-A
FMO
Forward scatter-height, forward scatter-area
Fluorescence minus one
ICA
IEQ
Independent component analysis
Islet equivalent
IIAM International Institute for the Advancement of Medicine
IIDP Integrated Islet Distribution program
IRF8 Interferon Regulatory Factor 8
mRNA messenger RNA
NDRI National Disease Research Interchange
nPOD Network for Pancreatic Organ Donors with Diabetes
PCA Principal component analysis
RIN RNA integrity number
SPI1 Spi-1 Proto-Oncogene
TMM Trimmed mean of M values
TPM Transcripts per kilobase million
t-SNE T-distributed stochastic neighbor embedding
UMI Unique molecular identifier
Total Word Count: 5,078    
Number of Figures: 8
Number of Tables: 0
Number of Supplementary Figures: 6
Number of Supplementary Tables: 3
Online Supplementary Material: 1
Page 3 of 54 Diabetes
3 
Abstract 
Type 1 diabetes studies consistently generate data showing islet β-cell dysfunction and T-cell 
mediated anti-β-cell specific autoimmunity. To explore the pathogenesis, we interrogated the β-
cell transcriptomes from donors with and without type 1 diabetes using both bulk-sorted and 
single β-cells. Consistent with immunohistological studies, β-cells from donors with type 1 
diabetes displayed increased Class I transcripts and associated mRNA species. These β-cells also 
expressed mRNA for Class II and Class II antigen presentation pathway components, but lacked 
macrophage marker, CD68. Immunohistological study of three independent recent-onset type 1 
diabetic donor cohorts showed Class II protein and its transcriptional regulator Class II major 
histocompatibility complex trans-activator (CIITA) protein expressed by a subset of insulin+ 
CD68- β-cells, specifically found in islets with lymphocytic infiltrates. β-cell surface expression 
of HLA Class II was detected on a portion of CD45-insulin+ β-cells from donors with type 1 
diabetes by immunofluorescence and flow cytometry. Our data demonstrate that pancreatic β-
cells from donors with type 1 diabetes express Class II molecules on selected cells with other key 
genes in those pathways and inflammation-associated genes. β-cell expression of Class II 
molecules suggests that β-cells may interact directly with islet-infiltrating CD4+ T-cells, and may 
play an immunopathogenic role. 
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The immune system plays a critical role in human type 1 diabetes pathogenesis. Varying 
proportions of T-cell subsets (CD8+ and CD4+) and B cells infiltrate the pancreatic islets (1) and 
target β-cells by recognizing type 1 diabetes-associated autoantigens (2, 3). The immunological 
mechanism(s) recruiting these cells to the islets had remained incompletely understood because 
until recently, islets from type 1 diabetic donors were not available for study. Antigen 
presentation to T-cells is mediated by antigen presenting cells (APCs) via two classes of HLA 
molecules: HLA Class I, recognized by CD8+-expressing T-cells, (Class I is present on nearly all 
nucleated cells), and HLA Class II, recognized by CD4+-expressing T-cells. Class II has a more 
limited tissue expression pattern, being present under most circumstances only on “professional” 
APCs, such as dendritic cells and macrophages (4).
Immunohistochemical studies of type 1 diabetic donor pancreas samples obtained at autopsy or 
by surgical biopsies (2, 5, 6, 7, 8, 9), have consistently reported islet cell “hyper-expression” of 
Class I molecules relative to that observed in non-diabetic donor pancreas sections. Even so, it 
was surprising when Bottazzo (10), Foulis (11) and others suggested that some β-cells from 
patients with type 1 diabetes also expressed HLA-DR Class II molecules (11, 12, 13, 14, 15, 
16). This pattern of expression by β-cells was termed “aberrant” as expression is absent from β-
cells in persons without type 1 diabetes. These reports raised the intriguing possibility that in 
individuals with type 1 diabetes, β-cell HLA-DR expression might allow direct presentation of 
autoantigens to infiltrating CD4+ T-cells (17). 
Several questions have been raised about these observations, not least because the identity of 
the islet cell subtypes affected was equivocal (18, 19). Some suggested that the cellular co-
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localization of insulin and Class II might reflect β-cells phagocytosed by scavenger immune 
cells (e.g. macrophages). Moreover, the functional significance of any expressed Class II was 
questioned since β-cells may not have the capacity to load these molecules with antigens. The 
immunological consequences of β-cell Class II expression have been debated (20, 21) and 
remain unclear (22).
Using isolated human islets from donors with and without type 1 diabetes, we performed RNA-
Seq of bulk sorted cells, single cell RNA-Seq of islet cells, and immunostaining of pancreatic 
islet sections and flow cytometry of dispersed islets to examine the β-cell specific expression of 
Class I and II molecules and associated regulatory genes. We now confirm that a subset of β-
cells from donors with type 1 diabetes express Class II mRNA and cell surface protein and co-
expresses CIITA, many other genes in the Class II pathway, and inflammation-associated gene 
products. The results indicate that β-cells can, when in a pro-inflammatory environment, 
upregulate Class II molecules in vivo. Overall, these results raise the possibility that β-cells may 
become involved in autoantigen presentation to CD4+ T-cells during the pathogenic process 
culminating in type 1 diabetes.
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RESEARCH DESIGN AND METHODS
Islets and Tissue
Isolated human islets from anonymous organ donors (exempt from Institutional Review Board 
review) were obtained through the Network of Pancreatic Organ Donors (nPOD), the Integrated 
Islet Distribution program (IIDP), Prodo Laboratories, Inc., or through the efforts of Vanderbilt 
University via either the National Disease Research Interchange (NDRI) or the International 
Institute for the Advancement of Medicine (IIAM). Supplementary Table 1 lists all donors with 
demographic information. Some type 1 diabetic donor samples were processed as described (3).
Islets were isolated for RNA-Seq from 13 donors without diabetes (nine males, four females, age 
range from 10-30 years old; 16.1 +/- 1.6, mean +/- SEM) and from 4 donors with type 1 diabetes 
(three males and one female, age range from 12-24 years old; 20.3 +/- 2.6) with disease durations 
of 0.42, 2, 3, and 7 years. 
Formalin-fixed paraffin embedded (FPPE) pancreas sections from donors with and without type 
1 diabetes were from the Exeter Archival Diabetes Biobank (EADB) (http://foulis.vub.ac.be/), 
the Diabetes Virus Detection (DiViD) study (8), and nPOD. The four EADB donors without 
diabetes included at least three males (the 4th’s gender was not reported) ranging in age from 5-
47 years (24.8 +/- 10.9). The 18 donors with type 1 diabetes (from all three cohorts) studied 
using immunohistology included eleven males and seven females ranging in age from 1- 42 
years (19.7 +/- 2.8 years) and with a range of disease duration of <1 week to 6 years (0.61 +/- 
0.34). Full ethical approval was available for all samples studied and all six DiViD study 
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participants provided written consent. 
Dissociation, Fixation, Staining, and Fluorescent Activated Cell Sorting (FACS)
Dissociation, fixation, and staining were as described previously (23), using the following stains: 
Zombie Violet Fixable Viability dye (BioLegend), anti-insulin Alexa fluor 647 (C27C9, Cell 
Signaling Technology), anti-glucagon (K79bB10, Sigma-Aldrich) labeled with Zenon Alexa 
fluor 568 and anti-somatostatin (7G5) labeled with Zenon Alexa fluor 488 (Thermo Fisher). Islet 
cells subsets (α-cells and β-cells) were sorted using a BD Biosciences FACSAria with the 
following gating strategy: live cells were selected based upon Zombie Violet dye exclusion. 
These cells were then selected based upon the presence or absence of an insulin positive signal. 
Insulin positive cells were further gated for single cells (FSC-H v. FSC-A) prior to sorting. All 
insulin negative cells were first gated for single cells and then gated for glucagon and 
somatostatin positive signals prior to sorting.
Cryopreserved non-diabetic donor islets (14149, 14128, 14219, and 14223) and cryopreserved 
islets from donors with type 1 diabetes (nPOD donors 6414, 6480, and 6323 and T1D.13, 
T1D.18, and T1D.19) were thawed (100-300 IEQ/aliquot) dispersed with Accutase™ (Stemcell 
Technologies), stained for viability (Live/dead Aqua™, Thermo Fisher), blocked with 50% 
human sera, and surface stained for CD45 (2D1, BioLegend) and +/- anti-HLA-DR (L243, 
BioLegend). After washing, cells were fixed, permeabilized and stained for intracellular insulin 
as described above. For treatment of fresh islets with proinflammatory cytokines, islets were 
cultured with IFN, IL-1, and TNF (R&D Systems) for 48 hours, dispersed with enzyme, and 
stained for viability before staining with anti-CD45 and anti-HLA-DR. Cells were washed, 
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fixed/permeabilized and stained intracellularly for insulin and glucagon as described. FMO 
controls were used to determine gates for each stain. Cells were run on a BD Biosciences LSRII 
and analyzed with FlowJo® (version 10.3) software.
RNA-Seq library construction, sequencing, gene expression, and statistical analysis
Sorted insulin+ and glucagon+ cells were pelleted and resuspended in Digestion Buffer and 
treated with Proteinase K for 3 hours at 50°C (RecoverAll, Thermo Fisher). The RecoverAll 
protocol for RNA isolation was followed for samples with at least 75,000 cells. For samples 
with less than 75,000 cells, nucleic acids were purified using Agencourt RNAClean XP beads 
(Beckman Coulter), digested with TURBO DNase (Thermo Fisher), and intact RNA was 
isolated with Agencourt RNAClean XP beads. RNAs were quantified using Qubit HS RNA 
(Thermo Fisher) and the Agilent Bioanalyzer RNA Pico chip was used to assess purity. Based 
upon RNA concentration and RNA integrity number (RIN), libraries were constructed using 
either the Ovation Human FFPE RNA-Seq Library System (NuGen) or the SMARTer Stranded 
Total RNA-Seq Kit (Pico Input Mammalian, Takara) and sequenced as 42bp paired-end reads 
on a NextSeq 500 (Illumina). We processed sequence data essentially as described in (24) 
using FastQC 0.10.1 for quality control analysis and FASTX-Toolkit version 0.0.13 to trim the 
low-quality ends of each read. Bowtie2 version 2.1.0 removed rRNA and snRNA, Tophat2 
version 2.0.14 mapped reads to the genome and transcriptome, RSEM version 1.2.28 and 
Bowtie version 0.12.9 quantified gene abundance. Harman (25) normalized batch effects in 
transcripts per kilobase million (TPM) count data to account for technical differences in library 
construction while maintaining biological variability. To normalize for gene length, TPM 
counts were converted to expected counts which we submitted to DESeq2 version 1.10.2 with 
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parametric fitting and row sum = 10 for differential gene expression analysis. For statistical 
analysis, the Wald test with Benjamini-Hochberg correction was used. All bulk and single cell 
RNA-Seq data is available in the Gene Expression Omnibus (GEO) repository (DataSet 
Identifier GSE121863).
inDrop™ single cell RNA-Seq gene expression and statistical analysis
Dissociated islets from selected preparations were droplet encapsulated and single cell RNA-Seq 
libraries were generated as described (26). Sequence output from NextSeq 500 was analyzed as 
described (27) except that an additional filtering step was added to the ESAT output, where the 
unique molecular identifier (UMI) for each ‘singleton’ (gene transcripts represented by only one 
read) was compared to the UMIs of all transcripts for that gene. If any transcript with at least two 
reads was only one base different from the singleton, the singleton was merged with the multi-
read transcript.
The islet cell subsets (α-cells and β-cells) were identified using a multistage process. In the initial 
stage, transcript count data subjected to TMM normalization (DESeq2), and principal component 
analysis (PCA, prcomp) was performed on the normalized data to identify genes that were most 
responsible for the variance in the data. Independent component analysis (ICA, fastICA) was 
applied for dimensionality reduction, followed by t-distributed stochastic neighbor embedding (t-
SNE, Rtsne) and density-based clustering. T-SNE groups cells into clusters based on the 
similarity of their entire transcriptomes, such that cells of a similar type form distinct clusters. 
Resulting clusters were examined to find the genes that were most differentially expressed in 
each cluster compared to all other cells. These differentially expressed genes were used to 
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identify and remove cell clusters that were not α- or β-cells: for instance, we identified acinar 
(where the majority of the cells in the cluster showed relatively high expression of CPA1, PRSS1, 
and PNLIP), ductal (high in KRT19) stellate (PDGFRB, COL1A1, ACTA2), vascular (PECAM1, 
ESM1, FLT1), professional APC (high HLA-DR) and δ or PP cells (respectively high expression 
of somatostatin and pancreatic polypeptide Y). The remaining cells were then re-normalized and 
clustered using the steps described above, resulting in 5 clusters. The cells in one of the clusters 
were mainly from the donor with type 1 diabetes, and showed high expression of both insulin 
and glucagon RNA. These rare events likely represent ‘doublets’, i.e. droplets containing more 
than one cell. The remaining cells formed four distinct clusters composed mainly of β-cells (high 
insulin mRNA expression) and α-cells (high glucagon mRNA expression) from the non-diabetic 
donor and the donor with type 1 diabetes. For differential expression analysis, we used the 
clusters to divide the cells into α- and β-cells, and used the sample label to distinguish between 
the donor without diabetes and the donor with type 1 diabetes. Genes with a Benjamini-
Hochberg adjusted p-value <0.05 were selected as differentially expressed, regardless of the log2 
fold-change difference. 
Immunostaining
A standard immunoperoxidase approach was used to examine single antigens on FFPE tissue 
sections (28). To examine multiple antigens within the same tissue, an immunofluorescence 
approach was employed in which antisera were applied sequentially (Supplementary Table 2). 
For some antibodies, the fluorescence signal was enhanced by tyramide signal amplification 
according the manufacturer’s instructions (Thermo Fisher). Images were captured using either a 
Leica AF6000 fluorescence microscope (Leica) or a Leica SP8 confocal instrument with a PL 
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APO 40X/1.25NA lens and 488 and 561 nm laser lines. Analysis of the images was performed 
using either LAS AF software (Leica) or Image J Version 1.50b Java 1.8.0-77. In some cases, 
Huygens deconvolution software was used to take high-resolution confocal images (SVI). 
Statistical Analysis
When two groups were compared, Student’s t-test or Wilcoxon Signed Rank test was used. 
Where more than two groups were compared, a one-way ANOVA was employed with Tukey 
post hoc test to determine the statistical significance. Results were considered statistically 
significant when p<0.05.   
Results
Bulk sorted β-cells from type 1 diabetic donors express Class I and Class I associated 
mRNA transcripts 
Human isolated islets (Supplementary Table 1) were dissociated and insulin+ -cells obtained 
by FACS were used to create RNA libraries. RNA-Seq was performed to determine -cell gene 
expression profiles from donors without diabetes (N=12; donor 17181 was only analyzed using 
inDrop™ single cell RNA-Seq) or those diagnosed with type 1 diabetes (N=4). Using a fold 
change of > 2 and p value < 0.05 as a cutoff to define differential expression, we found 650 
differentially expressed genes in -cells isolated from donors with type 1 diabetes (Fig. 1). 504 
genes were upregulated (red) while 146 others were downregulated (green). Class I and Class II 
pathway genes and pro-inflammatory-associated genes upregulated in the type 1 diabetic donor 
β-cells are labeled in the figure. Bulk FACS sorted type 1 diabetic donor -cells (relative to 
donors without diabetes) heterogeneously displayed upregulated mRNA expression of HLA-A, B, 
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C, and F Class I mRNA transcripts as well as the Class I transactivator mRNA NLRC5 (29). 
Gene expression levels ranged from 1.9 to 5.6-fold higher in the cohort of -cells with type 1 
diabetes, with significant p values ranging from 0.02 to 6.3x10-8 (Supplementary Fig. 1). These 
results were consistent with immunohistochemical studies on pancreata from donors with type 1 
diabetes (5, 6, 9, 29). In addition, genes for pro-inflammatory cytokines and associated factors 
were also found to be differentially expressed by -cells (IRF8, TNFRSF1B, TNF, IL1) (Fig. 1).
Bulk sorted β-cells from donors with type 1 diabetes express Class II and Class II related 
genes
Class II genes HLA-DPA1, DPB1, DRA, and DRB1 were also significantly upregulated in the 
type 1 diabetic donor -cells. Gene expression levels ranged from 18 to 52.4-fold at statistically 
significant p values ranging from 2.8x10-3 to 6.3x10-8 (Fig. 1 and 2A), highlighting the large 
donor to donor variability in gene expression and heterogeneous nature of HLA Class II pathway 
upregulation. Type 1 diabetic donor -cells differentially expressed additional genes in the Class 
II pathway including the Class II invariant chain CD74 and CIITA, the transcriptional regulator 
controlling Class II gene expression (Figs. 2A and 2B). We were not able to correlate expression 
of these factors and disease duration due to the variability seen in expression in these genes from 
the four donors with type 1 diabetes. Genes for two upstream CIITA transcriptional 
transactivators, IRF8 and SPI1, and the downstream CTSS (cathepsin S enzyme that cleaves 
CD74 to yield the CLIP fragment) were also expressed at higher levels in type 1 diabetic donor 
-cells relative to donors without diabetes (gene expression levels were increased by 5.9 to 54.8-
fold with p values between 5.8x10-3 and 6.7x10-14). These findings show that the mRNA for 
Class II HLA and other Class II molecules and associated factors are upregulated in the -cells 
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from donors with type 1 diabetes.
Single cell RNA-Seq reveals β-cell gene expression differences between a donor with type 1 
diabetes and a donor without diabetes.
Applying a complementary methodology to study the -cell population, single cells from 
dissociated islets were encapsulated using the inDrop™ system and prepared for RNA 
sequencing. Single islet cells (1,167 in total) from a 16-year-old donor without diabetes (donor 
17181) and from a 23-year-old diagnosed with type 1 diabetes five months before death (nPOD 
donor 6414; 1,235 cells in total) were collected and sequenced. -cells and -cells were 
identified based on the absence of endothelial, stellate, ductal, and other non-endocrine cell 
markers, and validated by the presence of glucagon and insulin hormone expression. tSNE plots 
clustered the cells into unique subpopulations based on their gene expression patterns. The -
cells and -cells separated into two subpopulations, predominately based on the donor’s diabetes 
status (Fig. 3A). In the donor without diabetes, 481/1,167 of the cells identified were -cells or 
-cells and there were approximately 0.84 -cells for every -cell. From the donor with type 1 
diabetes, 468/1,235 of the cells were -cells or -cells, with approximately 0.59 -cells for every 
-cell. Consistent with the bulk type 1 diabetic donor -cell population observations, the type 1 
diabetic donor’s -cells were more frequently positive for Class II and CD74 transcripts (Fig. 
3B) with 35.2% of the type 1 diabetic donor’s -cells expressing Class II and/or CD74 genes 
versus 7.8% of the -cells from the donor without diabetes, a 4.5-fold difference. 
Some -cells in type 1 diabetic donor islets co-express Class II and CIITA 
Type 1 diabetic donor pancreas section immunostaining revealed that Class II was expressed on 
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some cells within a subset of islets (Fig. 4 A-C). Class II expression was never observed in the 
non-diabetic donor pancreatic islet cells (Supplementary Table 3). Since the tissue used in these 
studies was recovered at autopsy, we also examined pancreas tissue collected by biopsy from six 
DiViD study living donors to obviate post mortem artifacts. In 5 of 6 DiViD cases, islet cells 
expressed Class II although the proportion of Class II immunopositive islets was variable, 
ranging from <10% in two cases to ~70% in another. From 4 pancreata from donors without 
diabetes (each containing between 50-100 islets), we found no islet CIITA expression (a 
representative image from one pancreas from a donor without diabetes, Fig. 4 D). However, in 
8/12 (67%) age-matched type 1 diabetic donor pancreata, strong CIITA immunostaining was 
detected in at least 1 islet on each section examined, (Fig. 4 E, F, G, I, J, L, M, O and 
Supplementary Table 3). Most sections from donors with type 1 diabetes contained multiple 
islets staining for CIITA and this was largely, but not exclusively restricted to -cells (Fig. 4 G-
I). Of 20 islets from 4 donors with type 1 diabetes, 74.9% of CIITA positive cells co-stained for 
insulin. Even though CIITA exerts its effect in the nucleus, the cytoplasmic staining pattern for 
CIITA was also seen in human tonsil tissue (Supplementary Fig. 2) which is similar to the 
cytoplasmic CIITA staining seen in islet -cells. Pancreas sections from two donors with type 1 
diabetes (nPOD 6414 and 6367) with Class II and Class II-associated mRNA species (like CIITA 
mRNA), also showed immunoreactive Class II and CIITA protein expression in insulin+ -cells 
(nPOD 6414, Fig. 4 M-O) and in certain insulin-negative islet cells (nPOD 6367, 
Supplementary Fig. 3A-D), confirming the transcriptome data. 
Surface expression of HLA Class II on insulin+ -cells was detected by co-localization with 
upregulated HLA-F expression on pancreas sections from donor E560 with type 1 diabetes (Fig. 
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5 A-E, Supplementary Fig. 3 E-G, and z-stack staining shown in Online Supplemental 
Material). Dispersed islets were analyzed for surface expression of CD45 and HLA-DR and 
intracellular expression of insulin by flow cytometry. Examples of CD45- and CD45+ cells from 
islets are shown (Supplementary Fig. 3 H-J). From donors with type 1 diabetes (N =6), 15.64% 
+/- 8.01 of CD45-insulin+ islet cells had detectable surface HLA-DR as compared to those cells 
from donors without diabetes (N = 4, 1.32% +/- 1.32) (Fig. 5 F-H). Islet cells (CD45- insulin+) 
from a donor without diabetes, that were treated with pro-inflammatory cytokines, upregulated 
surface HLA-DR (Supplementary Fig. 3 K and L and (30)).
Islet CIITA expression correlates with Class II, but not Class I or enterovirus VP1 
Using immunohistology to study a range of pancreata from donors without diabetes, we found no 
evidence of cells expressing CIITA or Class II in islets. Conversely, in all type 1 diabetic cases 
studied where CIITA positive islets were detected, islets expressing Class II were also present 
(Supplementary Table 3). We next employed co-immunofluorescence staining to localize 
CIITA and Class II within islets and found that all islet endocrine cells expressing Class II also 
co-expressed CIITA (Fig. 4 J-O) while occasional CIITA positive islet cells did not stain 
positively for Class II. 
In contrast to Class II mRNA species, the transcription of Class I genes is regulated by NLRC5 
in many cell types. Earlier studies did not find elevated NLRC5 by immunostaining or RNA 
array analysis in type 1 diabetic donor islets which hyperexpressed Class I (9, 31). Using 
methods with higher sensitivity, we observed clear evidence of upregulated NLRC5 mRNA in 
purified -cells from the donors with type 1 diabetes (Supplementary Fig. 1). We examined 
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whether some Class I expressing cells might have elevated CIITA expression. As expected, 
numerous insulin-containing type 1 diabetic donor islets hyper-expressed Class I in all endocrine 
cell subtypes (Supplementary Fig. 4 A-C). CIITA was not found in islets having normal levels 
of Class I expression, but was present in a few cells in some islets with upregulated Class I. 
Many islets with elevated Class I had no detectable CIITA. In common with Class II, the 
enteroviral capsid protein VP1 has also been detected in a small subset of type 1 diabetic donor 
-cells (32). CIITA was occasionally expressed in islets that also contained VP1-positive cells 
but, among a total of 29 VP1+ cells in 12 islets, the two antigens were never seen in the same 
cells (Supplementary Fig. 4 D-F). When pancreas sections were co-stained with antisera 
directed against Class I and Class II, all Class II+ β-cells had Class I expression, but many Class I 
positive islet cells had no detectable Class II (Supplementary Fig. 5).
Islet CIITA expression correlates with the number of islet-associated CD45+ cells.
Activated CD8+ T-cells secrete pro-inflammatory cytokines like IFNγ, which is reported to 
mediate CIITA (and thereby Class II) expression in certain non-hematopoietic cells (33, 34). Our 
immunohistological analysis suggested that islets with infiltrating or peri-islet CD45+ 
lymphocytes contained more CIITA positive islet cells. In general, islets with more than 25% of 
endocrine cells expressing CIITA also had large numbers of lymphocytes within, or in contact 
with, the islet boundary (Fig. 6A-C). Thus, CIITA expressing islets display greater numbers of 
infiltrating CD45+ cells as shown within individual donor sections (Fig. 6D), or when all type 1 
diabetic donor islet data were pooled (Fig. 6E). As expected, certain immune cells located either 
at the islet periphery or in other pancreas section areas, also stained for CIITA and Class II (Fig. 
6C and Supplementary Fig. 4 D and F).
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CIITA and insulin co-stained cells are not macrophages which have phagocytosed -cells
Since Class II and insulin expression within the same cell could be due to a professional APC 
engulfing a dead or damaged -cell, we co-stained for CIITA, CD68 (a macrophage marker) and 
insulin. We found no cells stained by all three antisera. In fact, we found no cells that were 
stained for both insulin and CD68, although multiple CD68 positive cells were found across the 
sections (Fig. 7 A-E). As expected, CD68 positive cells expressed CIITA, albeit at much lower 
levels than that seen in those islet endocrine cells where this transcription factor was detected.
Discussion
Several lines of evidence have suggested that β-cells are not simply passive victims of a T-cell 
mediated destructive process in type 1 diabetes. We now report data obtained using multiple 
methodologies confirming that Class II molecules and transcripts, along with other molecules in 
the Class II pathway, are expressed by a population of type 1 diabetic donor endocrine cells. The 
Class II expressing cells were predominantly β-cells, although islet cells that did not stain for 
insulin were also seen to express Class II. In addition to other islet endocrine cells, these cells 
might include de-granulated, dysfunctional and de-differentiating β-cells. Our conclusions are 
supported by immunohistological, flow cytometric, and mRNA expression assays, using both 
bulk sorted and single β-cells isolated from donors with type 1 diabetes. The transcriptomic 
analysis revealed that the β-cells display increased levels of genes associated with both Class II 
expression (including CIITA, IRF8 and SPI1) and function (CD74 and CTSS, gene for cathepsin 
S), supporting the conclusion that β-cell Class II expression is a bona fide phenomenon in human 
type 1 diabetes. Immunohistological analysis verified that the small complement of β-cells 
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expressing Class II also stain for CIITA, which was mainly located in the cytoplasm rather than 
in the nucleus. Nuclear CIITA has been visualized using GFP or FLAG-tagged CIITA (35, 36), 
or by using sufficient nuclear protein for Western blot detection. However, we were unable to 
detect CIITA protein in the nucleus of endocrine or immune cells in pancreas tissue sections, in 
human tonsillar tissue sections (Supplementary Fig. 2), or in cell lines with confirmed surface 
HLA-DR Class II expression, including human mature monocyte-derived dendritic cells, two B-
LCL cell lines, and a cell line transduced to express CIITA, CIITA-SupT1 (37) (data not shown). 
This is likely due to the blocking of the anti-CIITA antibody’s binding site in the N-terminal 
region of the protein which overlaps with domains that bind to basal transcriptional machinery 
(38). We were not able to detect CIITA by Western blot of the nuclear fraction of CD45-Class II+ 
cells sorted from proinflammatory cytokine-treated islets from donors without diabetes, most 
likely due to the insufficient quantity of nuclear protein recovered from the small number of cells 
sorted from dissociated islets, though we detected nuclear CIITA from B-LCL (data not shown). 
Even so, detection of Class II transcripts and proteins strongly indicates CIITA is performing its 
Class II transcriptional transactivation function in the nucleus. We also show that Class II and 
CIITA are absent from islet endocrine cells in individuals who do not have diabetes. The β-cell 
Class II upregulation appears to be unique to type 1 diabetes since it is not seen in people with 
type 2 diabetes or in other diseases of the pancreas such as cystic fibrosis or autoimmune 
pancreatitis (11).
Autoreactive CD8+ T-cells within islets of donors with type 1 diabetes (2, 3, 39), Class I 
expression and CD8-mediated β-cell killing, and in vitro hyperexpression of Class I on β-cells in 
in vitro models are well-established (40, 41). However, surface expression of Class II on β-cells 
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implies that β-cells may serve as APC and may directly play a role in the autoimmune response. 
As has been reported (30), in vitro treatment of islets with pro-inflammatory cytokines 
upregulated Class II expression on the surface of some β-cells, detected by flow cytometry 
(Supplementary Fig. 3K and L). Co-localized Class II and HLA-F (9), an upregulated gene 
product in the β-cells of type 1 diabetic donors (Supplementary Fig. 1), was detected on the 
surface of β-cells from a donor with type 1 diabetes by immunofluorescence (Fig. 5) in a pattern 
also seen on dendritic cells (42). In the dendritic cell study, 5% of total Class II expression was 
estimated to be on the cell surface. From cryopreserved islets of 6 donors with type 1 diabetes, as 
compared to those from 4 donors without diabetes, by flow cytometry, we detected HLA-DR 
expression, albeit at a low intensity, on the surface of a portion (15.64 +/- 8.01%) of CD45-
insulin+ cells despite known decreased insulin expression from cryopreserved human islets (43). 
In order to address the possibility that the co-localization of Class II with insulin-
immunopositivity in islets might reflect the phagocytosis of dead or dying β-cells by professional 
APCs (44) rather than by the β-cells per se, we stained sections with an anti-CD68 antibody to 
detect resident macrophages (45, 46). As expected, the islet macrophages expressed Class II but, 
interestingly, these were readily distinguished from Class II-expressing β-cells as the CD68+ 
cells displayed less intense CIITA immunostaining. We found no human islet macrophages that 
stained positively for CD68 and Class II and that also stained for insulin. 
We also show that CIITA expression is closely correlated with inflammation in the type 1 
diabetic donor islets, as judged by the presence of immune cells close to, or within, the islet 
boundary. Various lines of evidence suggest that certain pro-inflammatory cytokines (principally 
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IFNγ) can promote the expression of CIITA and Class II in non-hematopoietic cells and this has 
also been shown in islet cells (14, 47, 48, 49, 50). Hence, it is plausible that the local IFNγ 
associated with islet inflammation may drive β-cell Class II expression in type 1 diabetes. While 
this conclusion conflicts with other reports (11, 15), one potential explanation is the improved 
sensitivity of contemporary methods. 
CD8+ T-cells represent the most abundant cell type in the inflammatory infiltrates in individuals 
with type 1 diabetes (51, 52, 53) and since they can secrete IFNγ, it seems likely that infiltrating 
CD8+ T-cells may promote β-cell Class II expression. It is unclear why the response is restricted 
to only a few scattered β-cells within any given islet, since the islet infiltrating lymphocyte-
secreted cytokines should bathe most islet cells. One possibility is that the differential response 
may reflect the known heterogeneity among β-cells in vivo (53, 54, 55). Interestingly, several 
inflammatory-associated genes were found to be upregulated in β-cells from donors with type 1 
diabetes (IRF8, TNFRSF1B, TNF, IL-1), some of which are downstream of signaling by 
CXCL10, reported to be pivotal in recruiting immune cells to islets (56, 57, 58).
The β-cell CIITA and Class II expression now reported contrasts markedly with that reported for 
Class I which appears to be independent of inflammation (59). In support of a differential 
response, Class I hyperexpression was readily detected in islet cells that did not stain for CIITA 
and where no Class II was seen. Class I expression is often driven by the NLRC5 complex 
(Supplementary Fig. 6) and, in the present transcriptomic analysis, we found increased NLRC5 
mRNA in the type 1 diabetic donor β-cells. This result stands in contrast to earlier work where 
no increase in NLRC5 was detected either by RNA array analysis of laser capture micro-
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dissected islets from nPOD donors with type 1 diabetes or by immunostaining of islets in 
pancreas sections (9). The present data reinforce the conclusion that Class I is hyperexpressed on 
type 1 diabetic donor β-cells, and now suggest a role for NLRC5 in addition to STAT1 as 
previously shown (9).
The role of Class II-expressing professional APCs is to take up and process exogenous proteins, 
then present peptides in the context of Class II to CD4+ T-cells. In the Class II pathway (Fig. 8), 
we have depicted this as a ‘question mark’ as β-cells’ ability to take up exogenous antigen in this 
manner or present endogenous peptides is not known. A key question arising from this work is 
whether the β-cell Class II expression enables the cells to act within islets as surrogate APCs to 
CD4+ T-cells. Neither CD80 nor CD86 (costimulation required for effective presentation to 
naïve, but not memory T-cells) could be detected on the β-cells of patients with recent onset type 
1 diabetes (60), and we found no such staining in the present study (not shown). Whether other 
proteins could fulfill this costimulatory role is unknown. 
Taken as a whole, this study clarifies the much-debated suggestion that some β-cells from 
individuals with type 1 diabetes express Class II, as well as associated pathway genes and 
inflammatory pathway genes. Further work is needed to determine whether, and how, β-cell 
Class II expression contributes to type 1 diabetes pathogenesis. 
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Figure legends
Figure 1 - Volcano plot shows differential gene expression from bulk -cell populations and 
highlights upregulation of immune response specific genes in -cells from donors with type 1 
diabetes. -cells were isolated using FACS based on insulin expression from donors without 
diabetes (N=12) and with type 1 diabetes (N=4). RNA was isolated and libraries were 
sequenced. The volcano plot shows the 650 genes that are differentially (p<0.05 and fold-
change>2) upregulated (red circles, 504 genes) and downregulated (green circles, 146 genes) in 
the donors with type 1 diabetes. The lines point to individual circles and identify the -log10padjusted 
and log2FoldChange for specific genes. 
Figure 2- Differentially expressed RNA transcripts from sorted β-cell populations displaying the 
increased T1D donor gene expression of Class II, upstream regulatory genes for the Class II 
pathway, and downstream response element genes. Gene expression levels from donors without 
diabetes (N=12, open circles) and with T1D (N=4, filled shapes; circle: nPOD 6414, diamond: 
nPOD 6367, square: nPOD 6268, triangle: T1D.6) are shown on the ordinate (as expected counts 
of raw values calculated using RSEM) and the gene name, expression fold change, and adjusted 
p value are shown below the abscissa. Increased Class II associated gene expression is shown in 
(A), i.e. mRNA for 4 Class II chain proteins (HLA-DP alpha and beta chains, HLA-DR alpha and 
beta chains) and the Class II invariant chain CD74 in T1D donor β-cells and (B) Class II 
transactivator (CIITA) and its positive regulators IRF8 and SPI1, and CLIP cleavage protein 
CTSS which plays a critical role in antigen loading on Class II. Bars indicate the mean values 
+SEM. 
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Figure 3- Single cell transcriptome using inDrop™ single cell RNA-Seq analysis to separate 
and identify α-cells (triangles) and β-cells (circles) from two donors, a 16-year-old male 
without diabetes (open shapes; donor ID 17181) and a 23-year-old donor male with 0.42 years 
duration of T1D (filled shapes; nPOD 6414). Single α- and β-cells were identified as described 
in the methods and plotted by tSNE into the observed subpopulations. (A) α- and β-cells show 
two distinct subpopulations, depending on donor diabetes status. (B) Focusing only the β-cell 
subpopulation (indicated by the dotted arrows), CD74 and/or Class II positive β-cells (red 
circles) are 4.5 times more prevalent in the donor with T1D (filled circles) than the donor 
without diabetes (unfilled circles). 
Figure 4- Class II and CIITA are expressed in discrete islet endocrine cells in donors with T1D. 
Representative images of islets from donors with T1D from the EADB (A-B, E-L; E560 or 
E124B), (C) DiViD (DiViD 4), or nPOD (M-O, 6414) cohorts. Sections were immunostained 
with an antiserum raised against Class II protein (A-C, K, L, N, O), CIITA (D-G, I, J, L, M, O), 
and/or insulin (H, I, K, L, N, O) using either an immunoperoxidase (A-F) or 
immunofluorescence (G-O) approach. Representative images of pancreas sections probed with 
an antiserum against CIITA from either a healthy control individual (D, PM65/71) or from 
donors with T1D (E, F; E560, E124B). Black arrows indicate cells stained positively for Class II 
(B, C) or CIITA (E, F). (G-I) Representative immunofluorescence images from a pancreas from 
a donor with T1D (E560) probed for CIITA (G; red) and insulin (H; light blue). A merged image 
is shown (I). The red arrow indicates a cell positive for both CIITA and insulin. (J-O) 
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Representative images of T1D donor pancreas sections from EADB (J-L; E560) and nPOD (M-
O; 6414) were probed with CIITA (J, M; red), Class II protein (K, N; green) and insulin (K 
(inset), L, N (inset), O; light blue). Merged images are shown (L, O). Class II+insulin+CIITA+ 
cells are denoted by the white arrow in (L, O). The nPOD donor examined was part of the cohort 
from which RNA transcriptome data is shown in Figures 2 and 3. Scale bar (A,C-F) 50µm, (B,J-
O) 10µm, (G-I) 20µm.
Figure 5 - -cell expression of HLA-Class II (HLA-DR) and on the surface of a portion of 
CD45-insulin+ cells from donors with T1D. (A-E) Representative image of a pancreas section 
from a single donor with T1D (E560) stained for Class II (A, C-E; green), HLA-F (B-E; red) and 
insulin (D; light blue), with merged images shown (C-E). An enlargement of the highlighted area 
in panel D (dotted white box) is presented in A-C and E. A high-resolution image of the same 
cells is shown in Supplementary Fig. 3 and in Online Supplementary Material. Images were 
captured at x400 magnification unless otherwise stated; scale bar (A-E) 25µm. Cryopreserved, 
non-hand-picked islets (100-300 IEQ/stain) were thawed, washed, dispersed with enzyme, 
washed, stained for viability, washed and blocked with 50% human serum and then surface 
stained for CD45 and with and without anti-HLA-DR (L243 mAb). Cells were washed and 
stained for intracellular insulin as described in the methods. Single viable cells were analyzed for 
surface CD45 and intracellular insulin (left panels of each group). CD45-insulin+ cells were then 
analyzed for HLA-DR expression (middle and right panels of each group). Islets from donors 
without diabetes (14223, 14219, 14128. and 14149) are shown in (F). Islets from donors with 
type 1 diabetes (T1D.13, T1D.18, T1D.19, nPOD6323, nPOD6414, and nPOD6480; disease 
duration is indicated left of the sample identifier) are shown in (G). Samples from 14223 and 
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nPOD6480 were prepared and analyzed as a set, 14219 and nPOD6414 were prepared and 
analyzed as a set, and the remainder of the samples were prepared and analyzed as one set. Gates 
were set for FMO stains for each marker. For HLA-DR staining, this is shown for each sample. 
The percentage of CD45-insulin+HLA-DR+ cells for each sample are shown in Q2 for each 
sample (far right columns in F and G). A comparison of the frequencies of CD45-insulin+HLA-
DR+ cells for donors without diabetes and donors with type 1 diabetes is shown in (H) by 
Wilcoxon Signed Rank test. Donor samples nPOD6414, nPOD6367, and 14223 were analyzed 
for RNA transcriptome (Figs.1 and 2 and Supplementary Fig. 1).   
Figure 6- The number of CIITA positive islet cells in sections of pancreas from individuals with 
T1D correlates with the presence of infiltrating immune cells. (A-C) Representative images of 
pancreas sections from 3 donors with T1D stained for CD45 (red) or CIITA (green). Islets are 
highlighted with dashed lines and the images depict islets with either less than 25% of CIITA 
positive cells (A) or those containing more than 25% CIITA positive cells (B). An enlargement 
of the highlighted area (dotted white box) is also presented (C). Arrows indicate cells amongst 
the immune cell infiltrate positive for CIITA. Images were captured at x200 magnification. 
Multiple <25% and >25% CIITA+ islets were imaged in each of five pancreases from donors 
with T1D and the number of CD45+ cells within (or immediately adjacent to) each islet was 
counted. (D) Data are shown for each individual case studied and (E) for all cases combined. 
Bars indicate the mean values ±SEM. Scale bar, 20µm. **p<0.01, ***p<0.001. 
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Figure 7- Islet cells staining for CIITA and insulin are not CD68 immunopositive. 
Immunofluorescence staining of a pancreas section from a donor with T1D, probed for CIITA 
(A, B, D, E: red), CD68 (B, C, E: green) and insulin (B, E: light blue). Enlargement of the 
highlighted area (dotted white box) in the upper right panel is shown (C, D, E). The red arrow 
indicates an insulin positive cell which stained positively for CIITA but not CD68. The green 
arrow highlights a nearby CD68 immunopositive cell which is also positive for CIITA, but 
negative for insulin. The asterisks indicate areas of autofluorescence. Images captured at x400 
magnification; scale bar, 10µm. 
Figure 8- Upregulated protein and mRNA species in T1D donor β-cells from the Class II 
processing and presentation pathway. The observed upregulated proteins and mRNA species 
from the Class II processing and presentation pathway T1D donor β-cells are displayed 
according to their intracellular locations and with their functions. Depicted by symbols with 
black borders are upregulated proteins (red circles) and mRNA species (red rectangles), while 
putative upregulated proteins identified by upregulated mRNA species are shown with red ovals, 
diamonds or elongated ovals. Gray ovals depict mRNA species that were detected, but not 
upregulated in the β-cells from islets of donors with type 1 diabetes.
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 Figure 1 - Volcano plot shows differential gene expression from bulk β-cell populations and highlights 
upregulation of immune response specific genes in β-cells from donors with type 1 diabetes. β-cells were 
isolated using FACS based on insulin expression from donors without diabetes (N=12) and with type 1 
diabetes (N=4). RNA was isolated and libraries were sequenced. The volcano plot shows the 650 genes that 
are differentially (p<0.05 and fold-change>2) upregulated (red circles, 504 genes) and downregulated 
(green circles, 146 genes) in the donors with type 1 diabetes. The lines point to individual circles and 
identify the -log10padjusted and log2FoldChange for specific genes. 
279x215mm (150 x 150 DPI) 
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 Figure 2- Differentially expressed RNA transcripts from sorted β-cell populations displaying the increased 
T1D donor gene expression of Class II, upstream regulatory genes for the Class II pathway, and 
downstream response element genes. Gene expression levels from donors without diabetes (N=12, open 
circles) and with T1D (N=4, filled shapes; circle: nPOD 6414, diamond: nPOD 6367, square: nPOD 6268, 
triangle: T1D.6) are shown on the ordinate (as expected counts of raw values calculated using RSEM) and 
the gene name, expression fold change, and adjusted p value are shown below the abscissa. Increased 
Class II associated gene expression is shown in (A), i.e. mRNA for 4 Class II chain proteins (HLA-DP alpha 
and beta chains, HLA-DR alpha and beta chains) and the Class II invariant chain CD74 in T1D donor β-cells 
and (B) Class II transactivator (CIITA) and its positive regulators IRF8 and SPI1, and CLIP cleavage protein 
CTSS which plays a critical role in antigen loading on Class II. Bars indicate the mean values +SEM. 
279x215mm (150 x 150 DPI) 
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 Figure 3- Single cell transcriptome using inDrop™ single cell RNA-Seq analysis to separate and identify α-
cells (triangles) and β-cells (circles) from two donors, a 16-year-old male without diabetes (open shapes; 
donor ID 17181) and a 23-year-old donor male with 0.42 years duration of T1D (filled shapes; nPOD 6414). 
Single α- and β-cells were identified as described in the methods and plotted by tSNE into the observed 
subpopulations. (A) α- and β-cells show two distinct subpopulations, depending on donor diabetes status. 
(B) Focusing only the β-cell subpopulation (indicated by the dotted arrows), CD74 and/or Class II positive β-
cells (red circles) are 4.5 times more prevalent in the donor with T1D (filled circles) than the donor without 
diabetes (unfilled circles). 
279x215mm (150 x 150 DPI) 
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 Figure 4- Class II and CIITA are expressed in discrete islet endocrine cells in donors with T1D. 
Representative images of islets from donors with T1D from the EADB (A-B, E-L; E560 or E124B), (C) DiViD 
(DiViD 4), or nPOD (M-O, 6414) cohorts. Sections were immunostained with an antiserum raised against 
Class II protein (A-C, K, L, N, O), CIITA (D-G, I, J, L, M, O), and/or insulin (H, I, K, L, N, O) using either an 
immunoperoxidase (A-F) or immunofluorescence (G-O) approach. Representative images of pancreas 
sections probed with an antiserum against CIITA from either a healthy control individual (D, PM65/71) or 
from donors with T1D (E, F; E560, E124B). Black arrows indicate cells stained positively for Class II (B, C) 
or CIITA (E, F). (G-I) Representative immunofluorescence images from a pancreas from a donor with T1D 
(E560) probed for CIITA (G; red) and insulin (H; light blue). A merged image is shown (I). The red arrow 
indicates a cell positive for both CIITA and insulin. (J-O) Representative images of T1D donor pancreas 
sections from EADB (J-L; E560) and nPOD (M-O; 6414) were probed with CIITA (J, M; red), Class II protein 
(K, N; green) and insulin (K (inset), L, N (inset), O; light blue). Merged images are shown (L, O). Class 
II+insulin+CIITA+ cells are denoted by the white arrow in (L, O). The nPOD donor examined was part of the 
cohort from which RNA transcriptome data is shown in Figures 2 and 3. Scale bar (A,C-F) 50µm, (B,J-O) 
10µm, (G-I) 20µm. 
279x215mm (150 x 150 DPI) 
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 Figure 5 - β-cell expression of HLA-Class II (HLA-DR) and on the surface of a portion of CD45-insulin+ cells 
from donors with T1D. (A-E) Representative image of a pancreas section from a single donor with T1D 
(E560) stained for Class II (A, C-E; green), HLA-F (B-E; red) and insulin (D; light blue), with merged images 
shown (C-E). An enlargement of the highlighted area in panel D (dotted white box) is presented in A-C and 
E. A high-resolution image of the same cells is shown in Supplementary Fig. 3 and in Online Supplementary 
Material. Images were captured at x400 magnification unless otherwise stated; scale bar (A-E) 25µm. 
Cryopreserved, non-hand-picked islets (100-300 IEQ/stain) were thawed, washed, dispersed with enzyme, 
washed, stained for viability, washed and blocked with 50% human serum and then surface stained for 
CD45 and with and without anti-HLA-DR (L243 mAb). Cells were washed and stained for intracellular insulin 
as described in the methods. Single viable cells were analyzed for surface CD45 and intracellular insulin (left 
panels of each group). CD45-insulin+ cells were then analyzed for HLA-DR expression (middle and right 
panels of each group). Islets from donors without diabetes (14223, 14219, 14128. and 14149) are shown in 
(F). Islets from donors with type 1 diabetes (T1D.13, T1D.18, T1D.19, nPOD6323, nPOD6414, and 
nPOD6480; disease duration is indicated left of the sample identifier) are shown in (G). Samples from 14223 
and nPOD6480 were prepared and analyzed as a set, 14219 and nPOD6414 were prepared and analyzed as 
a set, and the remainder of the samples were prepared and analyzed as one set. Gates were set for FMO 
stains for each marker. For HLA-DR staining, this is shown for each sample. The percentage of CD45-
insulin+HLA-DR+ cells for each sample are shown in Q2 for each sample (far right columns in F and G). A 
comparison of the frequencies of CD45-insulin+HLA-DR+ cells for donors without diabetes and donors with 
type 1 diabetes is shown in (H) by Wilcoxon Signed Rank test. Donor samples nPOD6414, nPOD6367, and 
14223 were analyzed for RNA transcriptome (Figs.1 and 2 and Supplementary Fig. 1).   
279x215mm (150 x 150 DPI) 
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 Figure 6- The number of CIITA positive islet cells in sections of pancreas from individuals with T1D 
correlates with the presence of infiltrating immune cells. (A-C) Representative images of pancreas sections 
from 3 donors with T1D stained for CD45 (red) or CIITA (green). Islets are highlighted with dashed lines and 
the images depict islets with either less than 25% of CIITA positive cells (A) or those containing more than 
25% CIITA positive cells (B). An enlargement of the highlighted area (dotted white box) is also presented 
(C). Arrows indicate cells amongst the immune cell infiltrate positive for CIITA. Images were captured at 
x200 magnification. Multiple <25% and >25% CIITA+ islets were imaged in each of five pancreases from 
donors with T1D and the number of CD45+ cells within (or immediately adjacent to) each islet was counted. 
(D) Data are shown for each individual case studied and (E) for all cases combined. Bars indicate the mean 
values ±SEM. Scale bar, 20µm. **p<0.01, ***p<0.001. 
279x215mm (150 x 150 DPI) 
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 Figure 7- Islet cells staining for CIITA and insulin are not CD68 immunopositive. Immunofluorescence 
staining of a pancreas section from a donor with T1D, probed for CIITA (A, B, D, E: red), CD68 (B, C, E: 
green) and insulin (B, E: light blue). Enlargement of the highlighted area (dotted white box) in the upper 
right panel is shown (C, D, E). The red arrow indicates an insulin positive cell which stained positively for 
CIITA but not CD68. The green arrow highlights a nearby CD68 immunopositive cell which is also positive 
for CIITA, but negative for insulin. The asterisks indicate areas of autofluorescence. Images captured at 
x400 magnification; scale bar, 10µm. 
279x215mm (150 x 150 DPI) 
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 Figure 8- Upregulated protein and mRNA species in T1D donor β-cells from the Class II processing and 
presentation pathway. The observed upregulated proteins and mRNA species from the Class II processing 
and presentation pathway T1D donor β-cells are displayed according to their intracellular locations and with 
their functions. Depicted by symbols with black borders are upregulated proteins (red circles) and mRNA 
species (red rectangles), while putative upregulated proteins identified by upregulated mRNA species are 
shown with red ovals, diamonds or elongated ovals. Gray ovals depict mRNA species that were detected, but 
not upregulated in the β-cells from islets of donors with type 1 diabetes. 
279x215mm (150 x 150 DPI) 
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Supplementary Table and Figure Legends
Supplementary Table 1 - Demographics and identifiers of donor samples. Isolated -
cells from donors used for transcriptome analyses and tissue sections from donors 
without diabetes (w/o diabetes) and donors with type 1 diabetes used for 
immunohistochemical analyses (immunohistochemical and/or immunofluorescence, 
IHC/IF), RNA-Seq, or flow cytometry (FC) are listed from the EADB, DiViD, VU/UMass 
(VU/UMass cohort were obtained through a collaborative agreement with Vanderbilt 
University), or from UMass (from either Prodo Labs or IIDP, RRID codes) cohorts. 
Partial data previously described for the samples 13226 and 13255 in (23) and for 
T1D.6 in (3). N/A: not applicable. N/R: not reported. w, m, y: weeks, months, or years of 
disease duration.
Supplementary Table 2- Antibody details and immunocytochemistry conditions used 
for staining human pancreas specimens are detailed.
IHC; immunohistochemistry, IF; immunofluorescence.
Supplementary Table 3 - Case by case examination of CIITA and Class II staining. 
Green colour indicates cases in which CIITA was absent, whereas red colour demarks 
cases containing CIITA positive islets. ND: not determined. 
Supplementary Figure 1 - Bulk β cell population, as sorted by intracellular insulin 
staining, isolated from donors with type 1 diabetes shows increased HLA Class I 
expression. β cell gene expression (shown as expected counts of raw values calculated 
using RSEM) in donors without diabetes (N=12, open circles) and with type 1 diabetes 
(N=4, filled shapes, circle: nPOD 6414, diamond: nPOD 6367, square: nPOD 6268, 
triangle: T1D.6) are shown on the ordinate for 4 HLA Class I mRNA species (HLA-A, 
HLA-B, HLA-C, and HLA-F) and the HLA Class I transactivator, NLRC5. The fold 
change increase in expression from donors with type 1 diabetes and the adjusted p 
value are shown below the abscissa. Bars indicate the mean values +SEM. 
Supplementary Figure 2- CIITA is expressed in the tonsil, and has predominantly a 
cytosolic localisation. (A) Representative image of tonsil tissue from a single donor 
stained using an immunoperoxidase approach probed with an antibody raised against 
CIITA. An enlargement of the highlighted area (dotted white box) is presented (B). The 
white arrow indicates cells with high levels of cytoplasmic, but low nuclear CIITA. 
Images were captured at x400 magnification; scale bar (A) 50µm, (B) 20µm.
Supplementary Figure 3 – Surface expression of HLA Class II on -cells. From a 
single donor with T1D (nPOD 6367) from which RNA transcriptome data is shown in 
Figs. 1 and 2 and Supplementary Fig. 1, pancreas tissue was stained with antibodies to 
HLA Class II (green, A, D), insulin (light blue, B, D), and CIITA (red, C, D). Merged 
images are shown (D). White arrows denote a Class II+insulin-CIITA+ cell. Images 
captured at x400 magnification; scale bar, 10µm. A high-resolution image of the same 
cell shown in Fig. 5 (Fig. 5 A-D) was captured using deconvolution software at x630 
magnification with optical zoom (E-G). The yellow arrows indicate areas in which Class 
II and HLA-F co-localise. An entire z-stack of this region is presented as Online 
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Supplementary Material. CD45+ cells from islets are detected by flow cytometry. As 
described in Fig. 5, islets were dispersed and surface stained for CD45 and HLA-DR. 
Examples of the CD45- and CD45+ populations within two islet samples [nPOD6367 (an 
islet sample analyzed for transcriptome, Figs. 1 and 2) (H) and T1D.19 (I)] are shown. A 
representative profile of surface CD45+ cells for HLA-DR staining is shown for T1D.19 
(J). CD45- cells were then analyzed for surface HLA-DR and intracellular insulin as 
shown in Fig. 5. Representative plots are shown for islets for Induction of surface HLA 
Class II expression on islet β-cells by pro-inflammatory cytokines (K and L). 2000 IEQ 
from a control, non-diabetic donor (18076) were treated +/- proinflammatory cytokines 
as indicated in the figure for 48 hours. Islets were collected, dispersed with enzyme, 
stained with viability dye, blocked, surface stained for CD45 and HLA-DR (L243), 
washed, fixed/permeabilized and stained intracellularly for glucagon and insulin as 
described. Approximately 50% of insulin+ -cells upregulated surface HLA-DR upon 
treatment with proinflammatory cytokines. Similar results were seen with 3 other islet 
isolations.
Supplementary Figure 4 - CIITA expression does not correlate with the presence of 
Class I or enterovirus VP1, in the islets of donors with type 1 diabetes. Representative 
images from pancreas sections of individuals with type 1 diabetes stained with antisera 
raised against CIITA (A, red), Class I (B, green), Class II (D, red), VP1 (E, green) and 
insulin (C, F, light blue). Merged images are presented (C, F). White arrows in the upper 
panel (A-C) point to examples of CIITA immunopositive cells. White arrows (D-F, lower 
panels) indicate Class II positive cells that are negative for VP1. Yellow arrows show a 
VP1 positive cell which is immunonegative for Class II. Red arrows indicate an example 
of an immune cell that stains positive for HLA Class II in the islet periphery. Images 
captured at x400 magnification; scale bar 20µm.  
Supplementary Figure 5 - Class I and Class II expression do not correlate within islets. 
Representative immunofluorescence image of a pancreas section from a donor with 
type 1 diabetes stained for Class I (A, D: red), Class II (B, D: green) and insulin (C, D: 
light blue). The white arrow indicates an islet cell co-expressing Class I and Class II, 
whereas the yellow arrow marks a cell within the islet that is positive for Class I, but 
negative for Class II. Islet associated endothelial cells expressing Class II were also 
observed (green arrow). Images captured at x400 magnification; scale bars, 20µm. 
Supplementary Figure 6 - Upregulated protein and mRNA species in β cells from 
donors with type 1 diabetes from the HLA Class I processing and presentation pathway. 
The observed upregulated proteins and mRNA species from the HLA Class I processing 
and presentation pathway in β cells from donors with type 1 diabetes are displayed 
according to their intracellular locations and with their functions. Depicted by symbols 
with black borders are upregulated proteins (red circles) and mRNA species (red 
squares), while putative upregulated proteins identified by upregulated mRNA species 
are shown with red ovals, diamonds or elongated ovals, and gray ovals depict mRNA 
species that were detected, but not upregulated in the islets of donors with type 1 
diabetes. A detected, upregulated protein, STAT1 (9), but without mRNA detection, is 
indicated by an empty circle with a black border.
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Additional Online Supplementary Material Figure 1 - z-stack of HLA Class II and 
HLA -F co-localise on the surface of an islet cell in a donor with type 1 diabetes. A high-
resolution z-stack of the islet shown in Fig. 5 A-E and Supplementary Fig. 3A-D is 
presented. Sections from a donor with type 1 diabetes (E560) were stained with 
antisera against Class II (green) and HLA-F (red), with areas of co-localisation 
appearing yellow. This islet was imaged using deconvolution software at x630 
magnification with additional optical zoom. 
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